Literature DB >> 2941573

Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.

J R Seibold, C A Terregino.   

Abstract

In a double blind placebo crossover study, intravenous ketanserin, an antagonist of S2-serotonergic receptors, did not improve plethysmographically monitored digital blood flow during controlled cold challenge in 4 women with carefully defined primary Raynaud's phenomenon. However, ketanserin, if administered at the time of cold induced vasoconstriction, caused prompt vasodilation. These results suggest that serotonin is a contributory element in the maintenance of cold induced vasospasm but that other factors, presumedly adrenergic, initiate the vasoconstrictive response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941573

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Raynaud's syndrome.

Authors:  E D Cooke; A N Nicolaides
Journal:  BMJ       Date:  1990-03-03

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

4.  Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.

Authors:  B Marasini; M L Biondi; E Bianchi; P Dell'Orto; A Agostoni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.

Authors:  M Konishi; M Sakakura; N Tsushima
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

7.  Abnormal platelet aggregation in patients with Raynaud's phenomenon.

Authors:  M L Biondi; B Marasini
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

Review 8.  Oral vasodilators for primary Raynaud's phenomenon.

Authors:  Marlene Stewart; Joanne R Morling
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

9.  Vasodilators for primary Raynaud's phenomenon.

Authors:  Kevin Yc Su; Meghna Sharma; Hyunjun Jonathan Kim; Elizabeth Kaganov; Ian Hughes; Mohamed Hashim Abdeen; Jennifer Hwee Kwoon Ng
Journal:  Cochrane Database Syst Rev       Date:  2021-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.